Last quarter (Q4 2022), Destiny Pharma plc's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Destiny Pharma plc's net income was £―. See Destiny Pharma plc’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	£ 0.00	£ 0.00	£ 0.00
Cost of Revenue	-	-	-	£ 4.50M	£ 3.83M	-
Gross Profit	-	-	-	£ -4.50M	£ -3.83M	-
Operating Expense	-	£ 7.89M	£ 6.29M	£ 6.55M	£ 1.71M	£ 6.21M
Operating Income	-	£ -7.89M	£ -6.29M	£ -6.55M	£ -5.54M	£ -6.21M
Net Non Operating Interest Income Expense	-	£ 64.80K	£ -15.52K	£ 71.61K	£ 63.48K	£ 76.00K
Other Income Expense	-	£ -154.50K	-	-	-	-
Pretax Income	-	£ -7.71M	£ -6.27M	£ -6.48M	£ -5.52M	£ -6.01M
Tax Provision	-	£ -1.21M	£ -931.95K	£ -1.07M	£ -813.25K	£ -841.14K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -6.50M	£ -5.34M	£ -5.41M	£ -4.71M	£ -5.17M
Basic EPS	-	£ -0.09	£ -0.09	£ -0.12	£ -0.11	£ -0.12
Diluted EPS	-	£ -0.09	£ -0.09	£ -0.12	£ -0.11	£ -0.12
Basic Average Shares	-	£ 70.18M	£ 59.85M	£ 45.22M	£ 43.97M	£ 43.73M
Diluted Average Shares	-	£ 70.18M	£ 59.85M	£ 45.22M	£ 43.97M	£ 43.73M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	£ 7.89M	£ -6.29M	£ 6.55M	£ 5.54M	£ 6.21M
Net Income From Continuing And Discontinued Operation	-	£ -6.50M	£ -5.34M	£ -5.41M	£ -4.71M	£ -5.17M
Normalized Income	-	£ -8.92M	£ -7.20M	£ -5.41M	£ -4.71M	£ -5.17M
Interest Expense	-	-	-	-	-	-
EBIT	-	£ -7.71M	£ -6.27M	£ -6.55M	£ -5.54M	£ -6.21M
EBITDA	-	£ -7.70M	£ -6.27M	£ -6.54M	£ -5.52M	£ -6.20M

Currency in GBP

Destiny Pharma plc Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing